Acneiform eruption following anti-TNF-alpha treatment: A report of three cases

Journal of Drugs in Dermatology

Volumn 7, Issue 1, 2008, Pages 69-71

  Sun, Grace ^a   Wasko, Carina A ^a   Hsu, Sylvia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACNE; ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PSORIASIS;

ACNEIFORM ERUPTIONS; ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949160630     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Molecular Immunology. 1993;30:1443-1453.
2. Humira® [package insert]. North Chicago, IL: Abbott Laboratories; 2002.
3. Goldstein, SM, Wintroub, BU. Adverse Cutaneous Reactions to Medication: A Physician's Guide. New York, NY. CoMedica Inc; 1994:55
4. Katsanos KH, Christodouloum DK, Tsianos EV, Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol. 2002;97:2155-2156.
5. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540-1542. (Pubitemid 37523071)
6. Lebwohl B, Sapadin AN, Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49:275-276.
7. Shirakawa M, Uramoto K, Harada FA, Treatment of acne conglobata with infliximab. J Am Acad Dermatol. 2006;55:344-346. (Pubitemid 44037988)
8. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis. 2002;61:375-376. (Pubitemid 34257756)
9. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti- TNF-α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatol (Oxford). 2006;45:730-733. (Pubitemid 43985342)
10. Iqbal M, Kolodney MS. Acne fulminans with synovitis-acnepustulosis- hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol. 2005;52:S118-120.
11. Remicade® [product label]. Malvern, PA:Centocar;2006.
12. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Brit J Dermatol. 2007;156: 486-491.
13. Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol. 2006;5:251-254.
14. Bassi E, Poli F, Charachon A, Claudepierre P, Revuz J. Infliximab-induced acne: report of two cases. Brit J Dermatol. 2007;156:402-403. (Pubitemid 46095989)
15. Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalumimab. J Am Acad Dermatol. 2007; 56:S114-116.
16. Garcia Bartels N, Lee HH, Worm M, Burmester GR, Sterry W, Blume-Peytavi U. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol. 2006;142:1654-1655. (Pubitemid 44969233)